{"version":"1.0","provider_name":"CMC Pharma Solutions","provider_url":"https:\/\/www.cmcphsolutions.com\/es","author_name":"cmcphsolcmc","author_url":"https:\/\/www.cmcphsolutions.com\/es\/author\/cmcphsolcmc\/","title":"The European Commission approves Bavencio in combination with axitinib for advanced renal cell carcinoma | CMC Pharma Solutions","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"ovgUjNc1Fo\"><a href=\"https:\/\/www.cmcphsolutions.com\/es\/hola-mundo\/\">La Comisi\u00f3n Europea aprueba Bavencio en combinaci\u00f3n con axitinib para el carcinoma de c\u00e9lulas renales avanzado<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/www.cmcphsolutions.com\/es\/hola-mundo\/embed\/#?secret=ovgUjNc1Fo\" width=\"600\" height=\"338\" title=\"\u00abThe European Commission approves Bavencio in combination with axitinib for advanced renal cell carcinoma\u00bb \u2014 CMC Pharma Solutions\" data-secret=\"ovgUjNc1Fo\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script>\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n\/\/# sourceURL=https:\/\/www.cmcphsolutions.com\/wp-includes\/js\/wp-embed.min.js\n<\/script>","thumbnail_url":"https:\/\/www.cmcphsolutions.com\/wp-content\/uploads\/2019\/10\/ImageForArticle_180291-e1572971416226.jpg","thumbnail_width":581,"thumbnail_height":378,"description":"La aprobaci\u00f3n de la UE se basa en los resultados del ensayo JAVELIN Renal 101 que demuestran una mejora significativa en la supervivencia libre de progresi\u00f3n con avelumab en combinaci\u00f3n con axitinib, en comparaci\u00f3n con sunitinib. Esta aprobaci\u00f3n se aplica a todos los grupos de riesgo del IMDC, e independientemente de la expresi\u00f3n PD-L1. Merck [&hellip;]"}